Atezolizumab companion diagnostic - Roche

Drug Profile

Atezolizumab companion diagnostic - Roche

Alternative Names: MPDL3280A companion diagnostic; PD-L1 rabbit monoclonal immunohistochemistry antibody; Roche Tissue Diagnostics IHC assay; SP 142 immunohistochemistry antibody; Ventana PD-L1 (SP142) Assay

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Roche; Ventana Medical Systems
  • Class Monoclonal antibody diagnostics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Oct 2017 Launched for Urothelial bladder cancer (Diagnosis) and Non-small cell lung cancer (Diagnosis) in USA (unspecified route) before October 2017
  • 28 Sep 2017 Registered for Bladder cancer (Diagnosis) in European Union, Iceland, Iceland, Liechtenstein and Norway (unspecified route)
  • 28 Sep 2017 Registered for Non-small cell lung cancer (Diagnosis) in European Union, Iceland, Liechtenstein and Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top